With an aging population, chronic diseases such as cardiovascular disease, diabetes, chronic respiratory disease incidence increasing, and often the elderly are not necessarily due to these chronic diseases lethal. With the progression of disease, the elderly, the resistance to falling end-stage life, a lot of elderly result in death due to complications of pneumonia. Especially pneumonia caused by pneumococcus is the main killer of the elderly. The widespread use of antibiotics in the treatment of pneumonia, the bacteria has generated considerable resistance so difficult to treat. By pneumococcal infection, no matter what kind of treatment, five days before mortality are not reduced. This situation also exists in developed countries or developing countries. The research found that in the United States and Europe, hospitalized for pneumonia in the elderly, one-third in the past four years have hospitalized due to a variety of causes. Reduce the the elderly pneumonia opportunities, pneumococcal vaccination of older people, to enable them to acquire immunity against pneumococcal infection is an important measure used by many developed countries.
The pneumococcal polysaccharide vaccine is one of the effective ways. A recent U.S. study proved that elderly patients with chronic lung disease vaccination Niumo Law 23-valent pneumococcal polysaccharide vaccine reduces hospitalization due to pneumonia, the overall mortality rate is less than the control group compared with the unvaccinated control group for the elderly , the funding of the vaccine is much less than the cost of the treatment of pneumonia patients. The study shows that modern pneumococcal vaccine is not only used for the prevention of pneumococcal infections, it is an important means of protection to those suffering from chronic lung health of the elderly.